Role of interleukin-18 in acute graft-vs-host disease

Journal of Laboratory and Clinical Medicine

Volumn 141, Issue 6, 2003, Pages 365-371

  Reddy, Pavan ^a   Ferrara, James L M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; FAS ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; STAT4 PROTEIN; STAT6 PROTEIN;

BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL TRANSPLANTATION; CYTOKINE RELEASE; DISEASE SEVERITY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HELPER CELL; HEMATOPOIETIC CELL; IMMUNOLOGY; IMMUNOMODULATION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 0038133238     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(03)00028-3     Document Type: Review

References (57)

1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001;411:385-9.
2. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754-9.
3. Ferrara JLM, Deeg HJ. Graft versus host disease. N Engl J Med 1991;324:667-74.
4. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001;29:259-77.
5. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964-8.
6. Reddy P, Teshima T, Kukuruga M, Ordemann R, Liu C, Lowler K, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001;194:1433-40.
7. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378:88-91.
8. Bazan J, Timans J, Kastelein R. A newly defined interleukin-1? Nature 1996;379:591.
9. Hoshino K, Tsutsui H, Kawai T, Takeda K, Nakanishi K, Takeda Y, et al. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 1999;162:5041-4.
10. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, et al. Targeted disruption of the MyD88 gene results in loss of IL-1 and IL-18-mediated function. Immunity 1998;9:143-50.
11. Akira S. Role of IL-18 in innate immunity. Curr Opin Immunol 2000;12:59-63.
12. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both th1 and th2 responses. Annu Rev Immunol 2001;19:423-74.
13. Swain SL. Interleukin 18: tipping the balance towards a T helper cell 1 response. J Exp Med 2001;194:F11-4.
14. Okamoto I, Kohno K, Tanimoto T, Iwaki K, Ishihara T, Akamatsu S, et al. IL-18 prevents the development of chronic graft-versus-host disease in mice. J Immunol 2000;164:6067-74.
15. Fujimori Y. Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2000;109:652-7.
16. Nakamura H, Komatsu K, Ayaki M, Kawamoto S, Murakami M, Uoshima N, et al. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J Allergy Clin Immunol 2000;106:S45-50.
17. Zecchina G, Novick D, Rubinstein M, Barak V, Dinarello C, Nagler A. Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants. J Hematother Stem Cell Res 2001;10:769-76.
18. Hu HZ, Li GL, Lim YK, Chan SH, Yap EH. Kinetics of interferon-gamma secretion and its regulatory factors in the early phase of acute graft-versus-host disease. Immunology 1999;98:379-85.
19. Itoi H, Fujimori Y, Tsutsui H, Matsui K, Futatsugi S, Okamura H, et al. Fas ligand-induced caspase-1-dependent accumulation of interleukin-18 in mice with acute graft-versus-host disease. Blood 2001;98:235-7.
20. Hill G, Ferrara J. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754-9.
21. Teshima T, Hill G, Pan L, Brinson Y, van den Brink MR, Cooke K, et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 1999;104:317-25.
22. Liu Y, Janeway CA Jr. Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J Exp Med 1990;172:1735-9.
23. Novelli F, Bernabei P, Ozmen L, Rigamonti L, Allione A, Pestka S, et al. Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor. J Immunol 1996;157:1935-43.
24. Dalton DK, Haynes L, Chu CQ, Swain SL, Wittmer S. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med 2000;192:117-22.
25. Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000;1:469-74.
26. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 2002;196:999-1005.
27. Osaki T, Peron J-M, Cai Q, Okamura H, Robbins P, Kurimoto M, et al. IFN gamma inducing factor/IL-18 administration mediates IFN gamma and IL-12 independent antitumor effects. J Immunol 1998;160:1742-9.
28. Heuer JG, Tucker-McClung C, Hock RA. Neuroblastoma cells expressing mature IL-18, but not proIL-18, induce a strong and immediate antitumor immune response. J Immunother 1999;22:324-35.
29. Reddy P, Teshima T, Hildebrandt G, Duffner U, Maeda Y, Cooke KR, et al. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood 2002;100:3429-31.
30. Brok HPM, Heidt PJ, van der Meide PH, Zurcher C, Vossen JM. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993;151:6451-9.
31. Brok HPM, Vossen JM, Heidt PJ. Interferon-γ-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice. Bone Marrow Transplant 1997;19:601-6.
32. Sykes M, Romick ML, Sachs DH. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci U S A 1990;87:5633-7.
33. Dey BR, Yang YG, Szot GL, Pearson DA, Sykes M. Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion. Blood 1998;91:3315-22.
34. Sykes M, Pearson DA, Taylor PA, Szot GL, Goldman SJ, Blazar BR. Dose and timing of interleukin (IL)-I2 and timing and type of total-body irradiation: effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients. Biol Blood Marrow Transplant 1999;5:277-84.
35. Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 1998;102:2126-35.
36. Yang YG, Sykes M. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD. Leuk Lymphoma 1999;33:409-20.
37. Williamson E, Garside P, Bradley JA, More IAR, Mowat AM. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. J Immunol 1997;159:1208-15.
38. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995;86:2429-38.
39. Yang YG, Sergio JJ, Pearson DA, Szot GL, Sykes M. Interleukin 12 preserves the graft-vs-leukemia effect of allogeneic T cells while inhibiting graft-vs-host disease. Blood 1997;90:4651-60.
40. Welniak LA, Blazar BR, Wiltrout RH, Anver MR, Murphy WJ. Role of interleukin-12 in acute graft-versus-host disease. Transplant Proc 2001;33:1752-3.
41. Williamson E, Garside P, Bradley JA, Mowat AM. IL-12 is a central mediator of acute graft-versus-host disease in mice. J Immunol 1996;157:689-99.
42. Arnold D, Wasem C, Juillard P, Graber P, Cima I, Frutschi C, et al. IL-18-independent cytotoxic T lymphocyte activation and IFN-gamma production during experimental acute graft-versus-host disease. Int Immunol 2002;14:503-11.
43. Welniak LA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ. Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning. Biol Blood Marrow Transplant 2000;6:604-12.
44. Ogura T, Ueda H, Hosohara K, Tsuji R, Nagata Y, Kashiwamura S, et al. Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice. Blood 2001;98:2101-7.
45. Yoshimoto T, Mizutani H, Tsutsui H, Trauth N, Yamanaka K, Tanaka M, et al. IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT-6. Nat Immunol 2000;1:132-7.
46. Carson W, Dierksheide J, Jabbour S, Anghelina M, Bouchard P, Ku G, et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon gamma production and STAT-mediated signal transduction. Blood 2000;96:1465-73.
47. Okamoto M, Kato S, Oizumi K, Kinoshita M, Inoue Y, Hoshino K, et al. Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood 2002;99:1289-98.
48. Hoshino T, Yagita H, Ortaldo JR, Wiltrout RH, Young HA. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol 2000;30:1998-2006.
49. Hoshino T, Kawase Y, Okamoto M, Yokota K, Yoshino K, Yamamura K, et al. Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol 2001;166:7014-8.
50. Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev 2000;14:1693-711.
51. Robinson DS, O'Garra A. Further checkpoints in Th1 development. Immunity 2002;16:755-8.
52. Reddy P, Teshima T, Hildebrandt G, Williams DL, Liu C, Cooke KR, et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 2003;101:2877-85.
53. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001;344:655-64.
54. Li XC, Strom TB, Turka LA, Wells AD. T cell death and transplantation tolerance. Immunity 2001;14:407-16.
55. Farrar JD, Asnagli H, Murphy KM. T helper subset development: roles of instruction, selection, and transcription. J Clin Invest 2002;109:431-5.
56. Gracie AJ, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003;73:213-24.
57. Campbell E, Kunkel SL, Strieter RM, Lukacs NW. Differential roles of IL-18 in allergic airway disease: induction of eotaxin by resident cell populations exacerbates eosinophil accumulation. J Immunol 2000;164:1096-102.